SEC Form 10-Q filed by Solid Biosciences Inc.
$SLDB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2024 | $10.00 → $15.00 | Neutral → Overweight | JP Morgan |
| 6/24/2024 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 5/31/2024 | $20.00 | Overweight | Piper Sandler |
| 3/28/2024 | $40.00 | Outperform | William Blair |
| 3/15/2024 | $16.00 | Buy | Citigroup |
| 3/14/2024 | $8.00 → $20.00 | Neutral → Overweight | Piper Sandler |
| 12/8/2023 | $9.00 | Buy | H.C. Wainwright |
| 9/24/2021 | $20.00 → $17.00 | Buy | Chardan Capital |
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: Activities undertaken to accelerate development of SGT-003, including: expansion of study protocol in September 2024, activation of additional clinical sites in Q4 2024, additional manufacturing supply to support expanded trial enrollment - - CPVT: SGT-501 IND submission for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) on track for 1H 2025 - - Cash: Company ends Q3 2024 with approximately $171.1 million in cash, cash equivalents, and availab
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 9,741 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material to
CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Gabriel Brooks, M.D., Chief Medical Officer, will participate in a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on Thursday, November 7, 2024, at 1:45 p.m. ET in New York. Institutional investors interested in meeting with management during the conference may reach out to their Truist representatives. About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene thera
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
JP Morgan upgraded Solid Biosciences from Neutral to Overweight and set a new price target of $15.00 from $10.00 previously
Leerink Partners upgraded Solid Biosciences from Market Perform to Outperform and set a new price target of $12.00
Piper Sandler resumed coverage of Solid Biosciences with a rating of Overweight and set a new price target of $20.00
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including product candidates for Duchenne muscular dystrophy, Friedreich's ataxia, BAG3 mediated dilated cardiomyopathy and other undisclosed cardiac diseases, novel capsid libraries, and personnel - - Combined company is expected to have approximately $215 million in cash and investments, which is expected to fund the combined company into 2025 and support attainment of key milestones for lead gene therapy programs - - Companies to Host Confere
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid development to continue, supported by new preclinical data; Company anticipates early-2023 Investigational New Drug (IND) submission for SGT-003 for Duchenne - - Strategy and resource alignment support funding of operations through important clinical milestones and into Q2 2024 - - Solid Biosciences reports first quarter 2022 financial results; Company to hold conference call at 8:00am ET today - CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a li
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div
JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the price target from $10 to $15.
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
8-K - Solid Biosciences Inc. (0001707502) (Filer)